RX Surgipharma Private Limited
About RX Surgipharma Private Limited
Data last updated:
RX Surgipharma Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 22 September 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51909DL2017PTC324042. Its GSTIN is 07AAICR5395L1ZO (Delhi).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Murli Dhar Jha and Narender Kumar.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Off No – 4 Block – Ag – 1, Lscdda, New Delhi, Delhi, India – 110018.
As per the financials filed for FY 2025, the company reported a revenue of ₹32.61 Cr, a growth of 28% compared to the previous year. For the same year it recorded a net profit of ₹58.73 Lakh (net margin 1.8%) and EBITDA of ₹1.2 Cr (EBITDA margin 3.7%). Revenue has grown at a compounded annual rate (CAGR) of 40% over three years and 33% over five years.
As per MCA filings, the company has open charges of ₹5.63 Cr and satisfied charges of ₹1.51 Cr on record. Court records list 1 case involving the company, including 1 filed by the company.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressOff No – 4 Block – Ag – 1, Lscdda, New Delhi, Delhi, India – 110018
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of RX Surgipharma Private Limited
The main business activity of RX Surgipharma is trade. In detail, this covers retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of RX Surgipharma Private Limited FY 2024 filings available
RX Surgipharma Private Limited reported revenue of ₹32.61 Cr (up 28% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of RX Surgipharma Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 33% over five years, including 28% growth in the latest year. EBITDA rose 71% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of RX Surgipharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹1.2 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹58.73 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of RX Surgipharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.7% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of RX Surgipharma are in the company report.
Financial statements from FY 2018
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of RX Surgipharma Private Limited
RX Surgipharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nukind Healthcare Private Limited | ₹32.83 Cr (FY 2024) | •••• | •••• | 7.0% | •••• | New Delhi, Delhi, India |
| Grandeur Pharma Private Limited | ₹32.83 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | New Delhi, Delhi, India |
| Superlife Healthcare Private Limited | ₹32.82 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Kolkata, West Bengal, India |
| Vexxa Lifesciences Private Limited | ₹32.79 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Mumbai, Maharashtra, India |
| C P Thakkar and Company (Pharma) Limited | ₹32.76 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Mumbai, Maharashtra, India |
| RX Surgipharma Private Limited this company | ₹32.61 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | New Delhi, Delhi, India |
| Icarus Health Care Private Limited | ₹32.55 Cr (FY 2025) | •••• | •••• | -13.0% | •••• | Chennai, Tamil Nadu, India |
| MML Biotech Private Limited | ₹32.47 Cr (FY 2025) | •••• | •••• | -40.0% | •••• | Guntur, Andhra Pradesh, India |
| Exim Distributors Private Limited | ₹32.33 Cr (FY 2025) | •••• | •••• | -17.0% | •••• | Kolkata, West Bengal, India |
| Mento Vinimay Pvt.Ltd. | ₹32.25 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Siliguri, West Bengal, India |
| Shubh Medicorp (India) Private Limited | ₹32.12 Cr (FY 2024) | •••• | •••• | -24.0% | •••• | Pune, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below RX Surgipharma by revenue in the Pharma industry (Pharma Retail and Distribution), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of RX Surgipharma Private Limited
RX Surgipharma Private Limited is audited by KMRG & ASSOCIATES for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| KMRG & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of RX Surgipharma Private Limited
RX Surgipharma has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Murli Dhar Jha | Director | 22 Sep 2017 | 9 Years 0 Months | Current |
| Narender Kumar Also directs: Nephcore India Private Limited | Director | 18 Nov 2020 | 5 Years 10 Months | Current |
Ownership and Shareholding of RX Surgipharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of RX Surgipharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Apr 2025 | Others | ₹1.14 Cr | Open |
| 05 Dec 2024 | Others | ₹1.99 Cr | Open |
| 02 May 2024 | Others | ₹2.5 Cr | Open |
| 14 Mar 2023 | Yes Bank Limited | ₹1.51 Cr | Satisfied |
Total charge records: 4 View all charges
Legal Cases of RX Surgipharma Private Limited
RX Surgipharma Private Limited has 1 court case on record: 1 filed by RX Surgipharma. All case is disposed. Status as checked on 02 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South West, Delhi | Cheque dishonour complaint | Filed by the company against Aahan Pharma | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at RX Surgipharma Private Limited
Employment history and EPFO contributions of people linked to RX Surgipharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on RX Surgipharma Private Limited
RX Surgipharma Private Limited has 3 board changes on record since 2017: 2 appointments and 1 cessation. The latest: Nitin Sharma ceased to be Director on 13 May 2022.
1 earlier event is listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for RX Surgipharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by RX Surgipharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of RX Surgipharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of RX Surgipharma Private Limited
RX Surgipharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAICR5395L1ZO | Delhi | Active | 28 Sep 2018 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of RX Surgipharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RX Surgipharma Private Limited
RX Surgipharma is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 22 September 2017 (9+ years old) and is registered under CIN U51909DL2017PTC324042.
RX Surgipharma reported revenue of ₹32.61 Cr for FY 2025 (up 28% YoY).
RX Surgipharma has 2 current directors:
- Murli Dhar Jha - Director
- Narender Kumar - Director
RX Surgipharma reported a net profit of ₹58.73 Lakh (net margin 1.8%) and EBITDA of ₹1.2 Cr (EBITDA margin 3.7%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of RX Surgipharma is 40% over three years and 33% over five years. In the latest year (FY 2025) revenue rose 28%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of RX Surgipharma is 07AAICR5395L1ZO, registered in Delhi.
The CIN (Corporate Identification Number) of RX Surgipharma is U51909DL2017PTC324042. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
RX Surgipharma has 1 court case on record: 1 filed by the company.
RX Surgipharma was incorporated on 22 September 2017, making it 9+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of RX Surgipharma by revenue are Nukind Healthcare Private Limited, Grandeur Pharma Private Limited, Superlife Healthcare Private Limited, Vexxa Lifesciences Private Limited, C P Thakkar and Company (Pharma) Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution).
Nitin Sharma ceased to be Director on 13 May 2022. Narender Kumar was appointed as Director on 18 Nov 2020. Murli Dhar Jha was appointed as Director on 22 Sep 2017.